Rosetta Genomics said that its chief commercialization officer would resign as the company settles into its latest change in corporate direction. But the company is not the only player in the RNAi/microRNA space to experience changes to its management lineup.
The deal, which is independent of another arrangement under which Silence is developing siRNA drugs against AstraZeneca-specified targets, has been extended for one year.
Although RNAi can be used to knock down virtually any gene of interest, companies working in the space have taken a decidedly measured approach in building their internal pipelines, maintaining a relatively small number of drug-development programs.
The target, PKN-3, is a protein kinase C-related molecule associated with the growth of cancer cells, as well as metastasis formation, and is the target for the company's phase I siRNA-based solid tumor drug Atu-027.
The patent, DE 10066235, was granted in January 2008, and covers methods, uses, and medicaments of siRNAs, with a length between 15 and 49 nucleotides, expressed through a vector, according to Alnylam.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
